FDA seeks transparency task force comments
With a second public meeting scheduled for this fall, the FDA has reopened the comment period for its Transparency Task Force.
In the original notice of public meeting and request for comments this past June, the agency asked for comments on ways it could make information about its activities and decision making readily accessible to the public. With another public meeting scheduled, the FDA has now reopened the comment period to Nov. 6.
The task force is led by Joshua Sharfstein, FDA principal deputy commissioner, and also includes the agency’s center directors, associate commissioner for regulatory affairs, chief scientist and chief counsel.
In addition to soliciting comments, the agency also has established an online blog, expected to run through November, where interested observers can provide feedback on specific topics.
In the original notice of public meeting and request for comments this past June, the agency asked for comments on ways it could make information about its activities and decision making readily accessible to the public. With another public meeting scheduled, the FDA has now reopened the comment period to Nov. 6.
The task force is led by Joshua Sharfstein, FDA principal deputy commissioner, and also includes the agency’s center directors, associate commissioner for regulatory affairs, chief scientist and chief counsel.
In addition to soliciting comments, the agency also has established an online blog, expected to run through November, where interested observers can provide feedback on specific topics.